Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07179809
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Demographics/Lifestyle Survey — OTHERParticipants will complete all sessions and instruments
Study Details
The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.
Key Dates
- First listed
- Sep 18, 2025
- Start date
- Aug 21, 2026
- Status verified
- Aug 2026
- Primary completion
- Oct 1, 2027
- Completion
- Oct 1, 2029
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: ACLP ProgramParticipants will take part in the ACLP alone
- Experimental: ACLP Program + Learning CirclesParticipants will take part in the ACLP and Learning Circles
- Experimental: ACLP Program + Learning Circles + Individual Health CoachingParticipants will take part in the ACLP and in Learning Circles After participants complete the ACLP with Learning Circles, they will receive up to 6 individualized health coaching sessions.
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]
Central Contacts
- Meroe Morse, MD713-794-4053
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas M. D. Anderson Cancer Center | Houston | Texas | 77030 | Meroe Morse, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By condition
By specialty
Related Studies
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPHASE1/PHASE2 · Recruiting · Hoffmann-La Roche · Duarte, California
- A Study of BTX-A51 in People With Advanced Solid Tumor and Breast CancerPHASE1 · Recruiting · Edgewood Oncology Inc. · Lake Mary, Florida
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerPHASE1 · Recruiting · University of Texas Southwestern Medical Center · Chicago, Illinois
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPHASE1 · Recruiting · Relay Therapeutics, Inc. · Tucson, Arizona